vs

Side-by-side financial comparison of PDF SOLUTIONS INC (PDFS) and UroGen Pharma Ltd. (URGN). Click either name above to swap in a different company.

PDF SOLUTIONS INC is the larger business by last-quarter revenue ($62.4M vs $37.8M, roughly 1.6× UroGen Pharma Ltd.). On growth, UroGen Pharma Ltd. posted the faster year-over-year revenue change (54.0% vs 24.6%). PDF SOLUTIONS INC produced more free cash flow last quarter ($7.5M vs $-38.3M). Over the past eight quarters, UroGen Pharma Ltd.'s revenue compounded faster (41.9% CAGR vs 22.9%).

PDF Solutions, Inc. is an American multinational software and engineering services company based in Santa Clara, California. The company is listed in the Nasdaq stock exchange under the ticker symbol PDFS.

UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urological diseases and specialty cancers. Its core offerings target unmet medical needs for conditions including non-muscle invasive bladder cancer, with primary operations and sales markets across North America and Europe.

PDFS vs URGN — Head-to-Head

Bigger by revenue
PDFS
PDFS
1.6× larger
PDFS
$62.4M
$37.8M
URGN
Growing faster (revenue YoY)
URGN
URGN
+29.4% gap
URGN
54.0%
24.6%
PDFS
More free cash flow
PDFS
PDFS
$45.9M more FCF
PDFS
$7.5M
$-38.3M
URGN
Faster 2-yr revenue CAGR
URGN
URGN
Annualised
URGN
41.9%
22.9%
PDFS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PDFS
PDFS
URGN
URGN
Revenue
$62.4M
$37.8M
Net Profit
$-48.0K
Gross Margin
72.9%
91.3%
Operating Margin
5.5%
-50.5%
Net Margin
-0.1%
Revenue YoY
24.6%
54.0%
Net Profit YoY
-108.9%
EPS (diluted)
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PDFS
PDFS
URGN
URGN
Q4 25
$62.4M
$37.8M
Q3 25
$57.1M
$27.5M
Q2 25
$51.7M
$24.2M
Q1 25
$47.8M
$20.3M
Q4 24
$50.1M
$24.6M
Q3 24
$46.4M
$25.2M
Q2 24
$41.7M
$21.8M
Q1 24
$41.3M
$18.8M
Net Profit
PDFS
PDFS
URGN
URGN
Q4 25
$-48.0K
Q3 25
$1.3M
$-33.3M
Q2 25
$1.1M
$-49.9M
Q1 25
$-3.0M
$-43.8M
Q4 24
$539.0K
Q3 24
$2.2M
$-23.7M
Q2 24
$1.7M
$-33.4M
Q1 24
$-393.0K
$-32.3M
Gross Margin
PDFS
PDFS
URGN
URGN
Q4 25
72.9%
91.3%
Q3 25
72.3%
88.1%
Q2 25
71.2%
85.3%
Q1 25
72.9%
88.5%
Q4 24
68.3%
89.9%
Q3 24
73.1%
90.3%
Q2 24
70.6%
89.8%
Q1 24
67.3%
90.8%
Operating Margin
PDFS
PDFS
URGN
URGN
Q4 25
5.5%
-50.5%
Q3 25
8.5%
-99.7%
Q2 25
2.2%
-171.2%
Q1 25
-7.4%
-182.3%
Q4 24
1.0%
-112.6%
Q3 24
4.6%
-69.6%
Q2 24
0.6%
-118.3%
Q1 24
-4.7%
-137.1%
Net Margin
PDFS
PDFS
URGN
URGN
Q4 25
-0.1%
Q3 25
2.3%
-121.3%
Q2 25
2.2%
-206.2%
Q1 25
-6.3%
-216.5%
Q4 24
1.1%
Q3 24
4.8%
-93.9%
Q2 24
4.1%
-152.9%
Q1 24
-1.0%
-171.9%
EPS (diluted)
PDFS
PDFS
URGN
URGN
Q4 25
$0.00
Q3 25
$0.03
Q2 25
$0.03
Q1 25
$-0.08
Q4 24
$0.01
Q3 24
$0.06
Q2 24
$0.04
Q1 24
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PDFS
PDFS
URGN
URGN
Cash + ST InvestmentsLiquidity on hand
$42.2M
$160.1M
Total DebtLower is stronger
$67.0M
$125.0M
Stockholders' EquityBook value
$271.0M
$-105.5M
Total Assets
$418.7M
$200.5M
Debt / EquityLower = less leverage
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PDFS
PDFS
URGN
URGN
Q4 25
$42.2M
$160.1M
Q3 25
$35.9M
$153.8M
Q2 25
$40.4M
$176.0M
Q1 25
$54.1M
$216.1M
Q4 24
$114.9M
$282.7M
Q3 24
$120.2M
$278.9M
Q2 24
$117.9M
$272.3M
Q1 24
$122.9M
$183.2M
Total Debt
PDFS
PDFS
URGN
URGN
Q4 25
$67.0M
$125.0M
Q3 25
$67.6M
Q2 25
$68.1M
Q1 25
$68.7M
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
PDFS
PDFS
URGN
URGN
Q4 25
$271.0M
$-105.5M
Q3 25
$264.4M
$-115.4M
Q2 25
$257.5M
$-93.4M
Q1 25
$249.0M
$-46.5M
Q4 24
$246.0M
$-8.8M
Q3 24
$240.5M
$25.5M
Q2 24
$232.2M
$30.3M
Q1 24
$225.4M
$-40.1M
Total Assets
PDFS
PDFS
URGN
URGN
Q4 25
$418.7M
$200.5M
Q3 25
$406.4M
$185.0M
Q2 25
$391.1M
$208.7M
Q1 25
$390.0M
$247.6M
Q4 24
$315.3M
$285.7M
Q3 24
$307.4M
$301.9M
Q2 24
$298.0M
$281.8M
Q1 24
$286.8M
$200.6M
Debt / Equity
PDFS
PDFS
URGN
URGN
Q4 25
0.25×
Q3 25
0.26×
Q2 25
0.26×
Q1 25
0.28×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PDFS
PDFS
URGN
URGN
Operating Cash FlowLast quarter
$17.3M
$-38.3M
Free Cash FlowOCF − Capex
$7.5M
$-38.3M
FCF MarginFCF / Revenue
12.1%
-101.3%
Capex IntensityCapex / Revenue
15.7%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.6M
$-162.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PDFS
PDFS
URGN
URGN
Q4 25
$17.3M
$-38.3M
Q3 25
$3.3M
$-42.3M
Q2 25
$-5.2M
$-39.8M
Q1 25
$8.6M
$-42.0M
Q4 24
$1.6M
$-13.6M
Q3 24
$9.3M
$-27.7M
Q2 24
$684.0K
$-23.7M
Q1 24
$-1.9M
$-31.7M
Free Cash Flow
PDFS
PDFS
URGN
URGN
Q4 25
$7.5M
$-38.3M
Q3 25
$-2.9M
$-42.4M
Q2 25
$-13.8M
$-40.0M
Q1 25
$535.0K
$-42.1M
Q4 24
$-4.0M
$-13.7M
Q3 24
$5.1M
$-27.8M
Q2 24
$-4.6M
$-23.8M
Q1 24
$-3.9M
FCF Margin
PDFS
PDFS
URGN
URGN
Q4 25
12.1%
-101.3%
Q3 25
-5.1%
-154.1%
Q2 25
-26.6%
-165.0%
Q1 25
1.1%
-207.7%
Q4 24
-8.0%
-55.9%
Q3 24
11.0%
-110.1%
Q2 24
-11.1%
-109.1%
Q1 24
-9.4%
Capex Intensity
PDFS
PDFS
URGN
URGN
Q4 25
15.7%
0.0%
Q3 25
10.8%
0.3%
Q2 25
16.5%
0.6%
Q1 25
17.0%
0.2%
Q4 24
11.3%
0.5%
Q3 24
9.0%
0.4%
Q2 24
12.8%
0.4%
Q1 24
4.9%
0.0%
Cash Conversion
PDFS
PDFS
URGN
URGN
Q4 25
Q3 25
2.54×
Q2 25
-4.55×
Q1 25
Q4 24
2.98×
Q3 24
4.20×
Q2 24
0.40×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PDFS
PDFS

Volumebased$38.0M61%
Other$24.4M39%

URGN
URGN

Jelmyto$23.8M63%
Other$14.0M37%

Related Comparisons